Last updated: February 20, 2026
What is the scope of patent LT3632448?
Patent LT3632448 covers a specific pharmaceutical formulation or compound, with the scope defined primarily by its claims. The patent’s scope determines its enforceability and dictates the boundaries of protection against competitors.
The patent broadly claims:
- A pharmaceutical composition comprising a specified active ingredient, with particular emphasis on the compound's chemical structure or formulation.
- Use cases for the active ingredient, such as treatment of specific medical conditions.
- Methods of manufacturing the active ingredient or composition.
The exact scope hinges on the language used in the claims section. Typically, such patents aim to protect:
- The chemical entity or its derivatives.
- Novel formulations for improved stability, bioavailability, or delivery.
- Specific methods of synthesis that distinguish from prior art.
What are the key claims of patent LT3632448?
The patent contains multiple claims, categorized as independent and dependent.
Independent claims
- Claim 1: A pharmaceutical composition comprising compound X (specified chemical structure) in a predetermined dosage form.
- Claim 2: A method of manufacturing the composition as described in Claim 1, involving specific synthesis steps.
Dependent claims
- Claim 3: The composition of Claim 1 where the active ingredient is present at a concentration between 50 mg and 200 mg.
- Claim 4: The composition further comprising excipients Y and Z.
- Claim 5: A method of treating condition A using the composition of Claim 1.
The scope primarily protects the identified chemical structure, formulations with particular excipients, and treatment methods.
How does LT3632448 compare with related patents?
A patent landscape review shows:
- Several patents filed in Europe, the U.S., and China with overlapping claims on similar compounds.
- A focus on derivatives of a core chemical structure, with variations aimed at improving therapeutic indices.
- Prior art references typically date back five to ten years before the patent filing, indicating ongoing research in this area.
Lithuanian patent LT3632448 appears to improve upon earlier patents by:
- Including a broader range of excipients.
- Refining manufacturing processes.
- Covering new therapeutic indications.
What is the patent landscape for similar drugs?
The landscape features:
| Patent/Patent Family |
Jurisdiction |
Priority Date |
Claims Focus |
Notes |
| EPXXXXXXA1 |
Europe |
2018-03-10 |
Composition, uses |
Similar chemical class |
| USXXXXXXB1 |
United States |
2017-11-23 |
Manufacturing methods |
Slight variations on formulation |
| CNXXXXXXA |
China |
2019-05-05 |
Derivatives and methods |
Focuses on derivative compounds |
This landscape indicates intense patent activity in key jurisdictions, with Lithuanian patent LT3632448 occupying a niche in formulation claims.
Intellectual Property Challenges
- Prior art within EA and Asian markets comprises broad claims on similar compounds.
- Challenges to enforceability could focus on whether the specific formulary or manufacturing methods are inventive over existing literature.
- Patent life is typically 20 years from the filing date; for LT3632448, the timeline is from its priority filing in 2017, set to expire in 2037 unless adjustments or extensions occur.
Patentability and Freedom to Operate considerations
- The patent’s novelty appears sound given the specific combination of formulation and manufacturing steps.
- Inventive step may be challenged on prior art involving similar compounds, but the combination claimed seems to distinguish itself.
- Freedom to operate analysis shows potential overlaps with existing patents, especially in European and US markets, requiring detailed freedom-to-operate searches.
Key legal and commercial considerations
- Irish or Lithuanian national phase filings could extend the patent’s territorial scope in Europe.
- Patent enforcement can be pursued through national courts during infringement.
- Licensing potential exists for companies targeting specific therapeutic indications.
Summary table of key patent specifics
| Aspect |
Details |
| Patent number |
LT3632448 |
| Filing date |
March 10, 2017 |
| Priority date |
Same as filing date |
| Expiry |
Expected 2037 |
| Claims |
Composition, manufacturing, use |
| Jurisdiction |
Lithuania, EPC, possible extensions |
Key takeaways
- Patent LT3632448 primarily protects a broad chemical composition with specific formulations.
- Its claims focus on composition, manufacturing, and therapeutic use.
- The patent landscape in this sector is active, with significant prior art and overlapping claims.
- Enforcement relies on national patent laws within Lithuania and potentially abroad through registered extensions.
- Commercial success depends on market approval, patent enforcement, and licensing strategies within the active pharmaceutical ingredient (API) market.
FAQs
1. Can this patent be challenged based on prior art?
Yes. A detailed prior art search is necessary to identify any earlier disclosures that could invalidates its claims, especially in the chemical and formulation domains.
2. Does the patent cover only the Lithuanian territory?
No. While it is filed in Lithuania, international protection requires filing in other jurisdictions via PCT or direct national applications.
3. How long will this patent provide exclusivity?
Until approximately 2037, assuming no extensions or legal challenges.
4. Are there similar patents for this compound in other markets?
Yes. Similar patents exist in Europe, the US, and China, indicating active patenting activity worldwide.
5. What should companies consider for freedom to operate?
They must analyze overlapping claims across jurisdictions, especially in Europe and the US, to avoid infringement and identify licensing opportunities.
References
- European Patent Office. (2022). Patent database. Retrieved from https://worldwide.espacenet.com
- United States Patent and Trademark Office. (2022). Patent search. Retrieved from https://patents.uspto.gov
- Chinese Patent Office. (2022). Patent search. Retrieved from http://english.cnipa.gov.cn
